The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The sale is expected to close in the first quarter of 2022
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
In the interim, Deepak Khanna will lead Human Health International.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Recall does not include any metabolic deficiency nutrition formulas
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Subscribe To Our Newsletter & Stay Updated
